PMID- 23964994
OWN - NLM
STAT- MEDLINE
DCOM- 20140317
LR  - 20171116
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 15
IP  - 9
DP  - 2013 Sep
TI  - Variability of skin autofluorescence measurement over 6 and 12 weeks and the 
      influence of benfotiamine treatment.
PG  - 733-7
LID - 10.1089/dia.2013.0103 [doi]
AB  - BACKGROUND: Measurements of skin autofluorescence (SAF) allow for a simple and 
      noninvasive quantification of tissue advanced glycation end-products (AGEs), a 
      marker linked to the risk of diabetes complications. The aim of this study was to 
      test the repeatability of SAF over 6 and 12 weeks and to test whether 
      benfotiamine, a thiamine prodrug suggested to reduce AGEs formation under 
      hyperglycemic conditions, is able to attenuate SAF when administered over 6 
      weeks. PATIENTS AND METHODS: In a double-blind, placebo-controlled, randomized, 
      crossover study, 22 patients with type 2 diabetes mellitus (T2DM) received 
      900 mg/day benfotiamine or placebo for 6 weeks (washout period of 6 weeks 
      between). At the beginning and at the end of each treatment period, SAF was 
      assessed in the fasting state, as well as 2, 4, and 6 h following a mixed test 
      meal. RESULTS: The respective intra-individual and inter-individual variability 
      of fasting SAF was 6.9% and 24.5% within 6 weeks and 10.9% and 23.1% within 12 
      weeks. The respective variability calculated for triplicate comparisons was 9.9% 
      and 27.7%. A short-term therapy with benfotiamine did not influence SAF 
      significantly, nor did we find a significant postprandial SAF increase. 
      CONCLUSIONS: In patients with T2DM, repeated, timely spaced SAF measurements have 
      an intra-subject variability of below 11%. Using these data, sample sizes were 
      calculated for interventional studies aiming at reducing SAF. Benfotiamine 
      treatment for 6 weeks did not significantly influence SAF; for this, a 
      longer-term therapy is probably needed.
FAU - Stirban, Alin
AU  - Stirban A
AD  - Diabetes Clinic, Heart and Diabetes Center NR, Ruhr University Bochum, Bad 
      Oeynhausen, Germany. alin.stirban@profil.com
FAU - Pop, Alexandra
AU  - Pop A
FAU - Fischer, Annelie
AU  - Fischer A
FAU - Heckermann, Sascha
AU  - Heckermann S
FAU - Tschoepe, Diethelm
AU  - Tschoepe D
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130821
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Chelating Agents)
RN  - 0 (Glycation End Products, Advanced)
RN  - X66NSO3N35 (Thiamine)
RN  - Y92OUS2H9B (benphothiamine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chelating Agents/*therapeutic use
MH  - Cross-Over Studies
MH  - Diabetes Complications/*diagnosis/*drug therapy
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Fluorescence
MH  - Glycation End Products, Advanced/metabolism
MH  - Humans
MH  - Hyperglycemia/blood
MH  - Male
MH  - Middle Aged
MH  - Postprandial Period/physiology
MH  - Reproducibility of Results
MH  - Skin/*drug effects
MH  - Thiamine/*analogs & derivatives/therapeutic use
EDAT- 2013/08/24 06:00
MHDA- 2014/03/19 06:00
CRDT- 2013/08/23 06:00
PHST- 2013/08/23 06:00 [entrez]
PHST- 2013/08/24 06:00 [pubmed]
PHST- 2014/03/19 06:00 [medline]
AID - 10.1089/dia.2013.0103 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2013 Sep;15(9):733-7. doi: 10.1089/dia.2013.0103. Epub 
      2013 Aug 21.